Nothing Special   »   [go: up one dir, main page]

WO2004073587A3 - Diagnostics et traitements de maladies associees au recepteur de la parathormone 1 (pthr1) - Google Patents

Diagnostics et traitements de maladies associees au recepteur de la parathormone 1 (pthr1) Download PDF

Info

Publication number
WO2004073587A3
WO2004073587A3 PCT/EP2004/001099 EP2004001099W WO2004073587A3 WO 2004073587 A3 WO2004073587 A3 WO 2004073587A3 EP 2004001099 W EP2004001099 W EP 2004001099W WO 2004073587 A3 WO2004073587 A3 WO 2004073587A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
disorders
pthr1
therapeutics
diagnostics
Prior art date
Application number
PCT/EP2004/001099
Other languages
English (en)
Other versions
WO2004073587A2 (fr
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts filed Critical Bayer Healthcare Ag
Publication of WO2004073587A2 publication Critical patent/WO2004073587A2/fr
Publication of WO2004073587A3 publication Critical patent/WO2004073587A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne un PTHR1 humain qui est associé aux maladies cardio-vasculaires, aux troubles du système nerveux périphérique et central, à l'inflammation, aux maladies urologiques, aux troubles du développement, au cancer, aux maladies métaboliques, aux maladies endocrinologiques et aux troubles du système gastro-intestinal. L'invention concerne également des dosages permettant d'identifier des composés utiles dans le traitement ou la prévention des maladies cardio-vasculaires, des troubles du système nerveux périphérique et central, de l'inflammation, des maladies urologiques, des troubles du développement, du cancer, des maladies métaboliques, des maladies endocrinologiques et des troubles du système gastro-intestinal. L'invention concerne également des composés qui se lient à PTHR1 et/ou activent ou inhibent l'activité de PTHR1 ainsi que des compositions pharmaceutiques comprenant ces composés.
PCT/EP2004/001099 2003-02-19 2004-02-06 Diagnostics et traitements de maladies associees au recepteur de la parathormone 1 (pthr1) WO2004073587A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03003174 2003-02-19
EP03003174.4 2003-02-19

Publications (2)

Publication Number Publication Date
WO2004073587A2 WO2004073587A2 (fr) 2004-09-02
WO2004073587A3 true WO2004073587A3 (fr) 2005-01-06

Family

ID=32892845

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/001099 WO2004073587A2 (fr) 2003-02-19 2004-02-06 Diagnostics et traitements de maladies associees au recepteur de la parathormone 1 (pthr1)

Country Status (1)

Country Link
WO (1) WO2004073587A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3490600A1 (fr) 2016-08-01 2019-06-05 Xoma (Us) Llc Anticorps du récepteur 1 de l'hormone de parathyroïde (pth1r) et leurs utilisations
CA3217862A1 (fr) 2021-05-05 2022-11-10 Radius Pharmaceuticals, Inc. Modele animal ayant une recombinaison homologue du recepteur pth1 de souris

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998051324A1 (fr) * 1997-05-14 1998-11-19 Rhone-Poulenc Rorer Pharmaceuticals Inc. Analogues peptidiques de l'hormone parathyroide
US5840853A (en) * 1991-04-05 1998-11-24 The General Hospital Corporation Parathyroid hormone receptor and DNA encoding same
WO2001009328A1 (fr) * 1999-08-03 2001-02-08 Millennium Pharmaceuticals, Inc. Nouvelle molecule 15571 de type gpcr de la famille secretine et utilisations de cette derniere
WO2001077172A2 (fr) * 2000-04-07 2001-10-18 Arena Pharmaceuticals, Inc. Recepteurs connus couples a la proteine g non endogenes a activation constitutive
WO2002061087A2 (fr) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Peptides antigeniques destines a des recepteurs couples a la proteine g (gpcr), anticorps s'y rapportant, et systeme d'identification desdits peptides antigeniques

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840853A (en) * 1991-04-05 1998-11-24 The General Hospital Corporation Parathyroid hormone receptor and DNA encoding same
WO1998051324A1 (fr) * 1997-05-14 1998-11-19 Rhone-Poulenc Rorer Pharmaceuticals Inc. Analogues peptidiques de l'hormone parathyroide
WO2001009328A1 (fr) * 1999-08-03 2001-02-08 Millennium Pharmaceuticals, Inc. Nouvelle molecule 15571 de type gpcr de la famille secretine et utilisations de cette derniere
WO2001077172A2 (fr) * 2000-04-07 2001-10-18 Arena Pharmaceuticals, Inc. Recepteurs connus couples a la proteine g non endogenes a activation constitutive
WO2002061087A2 (fr) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Peptides antigeniques destines a des recepteurs couples a la proteine g (gpcr), anticorps s'y rapportant, et systeme d'identification desdits peptides antigeniques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
QIAN J ET AL: "REDUCED BLOOD PRESSURE AND INCREASED SENSITIVITY OF THE VASCULATURE TO PARATHYROID HORMONE-RELATED PROTEIN (PTHRP) IN TRANSGENIC MICE OVEREXPRESSING THE PTH/PTHRP RECEPTOR IN VASCULAR SMOOTH MUSCLE", ENDOCRINOLOGY, BALTIMORE, MD, US, vol. 140, no. 4, April 1999 (1999-04-01), pages 1826 - 1833, XP001193328, ISSN: 0013-7227 *

Also Published As

Publication number Publication date
WO2004073587A2 (fr) 2004-09-02

Similar Documents

Publication Publication Date Title
WO2005093092A3 (fr) Diagnostic et traitement de maladies associees au recepteur 44 couple aux proteines g (gpr44)
WO2004097421A3 (fr) Diagnostics et traitements destines a des maladies associees au recepteur de type recepteur calcitonine (calcrl)
WO2004073587A3 (fr) Diagnostics et traitements de maladies associees au recepteur de la parathormone 1 (pthr1)
WO2004042402A3 (fr) Moyens diagnostiques et therapeutiques destines a des maladies associees au mrgx1 humain
WO2004099782A3 (fr) Approche diagnostique et therapeutique des maladies associees au recepteur gpr39 (gpr39) couple a une proteine g
WO2004038405A3 (fr) Diagnostics et therapeutiques pour maladies liees au recepteur 43 couple a la proteine g (gpr43)
WO2004099783A3 (fr) Diagnostics et therapies destines a des maladies associees au recepteur ltb4 (ltb4) couple a la proteine g
WO2004071378A3 (fr) Methodes diagnostiques et therapeutiques relatives a des etats pathologiques lies au recepteur hm74a couple a la proteine g
WO2004082570A3 (fr) Diagnostics et traitements contre des maladies associees au recepteur d2 de la dopamine (drd2)
WO2004106935A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur 103 couples aux proteines g (gpr103)
WO2004038421A3 (fr) Agents diagnostiques et therapeutiques pour maladies associees au recepteur 41 couple a une proteine g humaine (gpr41)
WO2004071396A3 (fr) Diagnostics et therapeutique pour des maladies associees au recepteur 2 de l'hormone parathyroide (pthr2)
WO2005074969A3 (fr) Diagnostics et traitements de maladies associees au recepteur nucleaire humain nr4a1 (nr4a1)
WO2004048978A3 (fr) Procedes pour diagnostiquer et traiter des maladies associees au recepteur 37 couple a la proteine g d'acide biliaire (bg37)
WO2004099248A3 (fr) Produits de diagnostic et de traitement de maladies associees au recepteur agtr2 couple aux proteines g (agtr2)
WO2004071393A3 (fr) Diagnostic et therapeutique pour des maladies associees au recepteur peptide 1 de type glucagon
WO2003066077A3 (fr) Outil de diagnostic et therapeutique pour des maladies associees au recepteur de neuromedine u1 (nmu1)
WO2004042077A3 (fr) Diagnostics et traitements de maladies associees a la phosphodiesterase 8b humaine (pde8b)
WO2005101001A3 (fr) Methodes diagnostiques et therapeutiques pour lutter contre des maladies associees au recepteur couple a la proteine g, element c, groupe 5, famille c (gprc5c)
WO2004099781A3 (fr) Approches diagnostique et therapeutique des maladies associees au recepteur rdc1 (rdc1) couple a une proteine g
WO2003076945A3 (fr) Diagnostic et therapie de maladies associees au recepteur couple a la proteine g 105 (gpr105)
WO2005040790A3 (fr) Diagnostics et therapeutiques pour maladies liees au recepteur 75 couple a la proteine g (gpr75)
WO2005108998A3 (fr) Methodes de diagnostic et de traitement de maladies associees au recepteur couple aux proteines g adrenergique beta-3 (adrb3)
WO2005075983A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees a un recepteur nucleaire humain nr4a3 (nr4a3)
WO2004038416A8 (fr) Diagnostic et therapeutique de maladies associees au recepteur 6 couple a la proteine g humain (gpr6)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase